Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CANbridge Doses First Patient in Phase II GBM Trial

publication date: Oct 27, 2021

CANbridge, a Beijing rare disease/cancer biopharma, dosed the first patient in a China Phase II trial in patients with glioblastoma multiforme. CAN008 is a CD95 Fc fusion protein that blocks the interaction between CD95 receptor and its cognate ligand CD95L by binding to CD95L. The trial will investigate efficacy and explore select biomarkers. CANbridge in-licensed greater China rights to the anti-TNF drug candidate, which has been granted orphan drug designation in the US and EU, from Germany's Apogenix. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital